A/Prof Steve McGloughlin
Director of Intensive Care, The Alfred Hospital, Australia
Steve completed diverse clinical training in intensive care, training in units in the United Kingdom, Queensland and the Northern Territory. He has completed a paediatric intensive care fellowship at the Mater Children’s Hospital, in Brisbane. He has also worked for the Royal Flying Doctor Service in Northern Queensland. In addition to intensive care he is an infectious diseases specialist and continues to work in this capacity at the Alfred and has completed a Masters of Public Health and Tropical Medicine.
Steve’s specific research and clinical interests include infections in critically ill patients and sepsis. He is the lead author for the Australian Therapeutic Guidelines chapter on Severe Sepsis and a member of the surviving sepsis international collaboration. During the COVID-19 pandemic he was the lead author of the ANZICS COVID-19 guideline and a the lead of the National COVID-19 Evidence Based Taskforce critical panel and a member of the infection prevention panel.
Steve was appointed Director of the Alfred ICU in 2017 and has completed a Masters of Health Leadership from McGill university.
CME Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The speaker did not report any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.
Despite the advances of modern critical care, there is remarkably little that has been demonstrated to change the trajectory of septic shock. We still rely on early recognition, good supportive care and appropriate antimicrobials to help these patients. This talk will focus on why these therapies are still the mainstays and how we need to work hard to ensure that in the near future – novel therapies and complex supportive care mechanisms such as ECMO can help the sickest patients.
By the end of this lecture the attendee will be able to:
- Demonstrate why preventing the deterioration from sepsis to septic shock is the key to good patient outcomes.
- Summarise current best practice for the support of a patient with profound septic shock.
- Review the evidence for novel methods of critical care support for patients with septic shock including ECMO.
- Review the potential use of ECMO in Sepsis management
Additional CME Info
Release Date: February 1, 2020, Termination Date: January 31, 2023
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EB Medicine and Continulus. EB Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: EB Medicine designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™ per lecture. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity received no commercial support.
Earning Credit: In order to earn CME credit, the participant must take the pre-test, listen to the lecture, take the CME post-test, and complete the post-test evaluation.